The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack

Cancer Research

Volumn 70, Issue 5, 2010, Pages 1825-1834

  Seeger, Jens Michael ^a   Schmidt, Patrick ^a   Brinkmann, Kerstin ^a   Hombach, Andreas A ^a   Coutelle, Oliver ^a   Zigrino, Paola ^a   Wagner Stippich, Diana ^a   Mauch, Cornelia ^a   Abken, Hinrich ^a   Krönke, Martin ^a   Kashkar, Hamid ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 8; GRANZYME B; MELANOMA ANTIGEN; PROTEASOME INHIBITOR; PROTEIN NOXA;

ANALYSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; MELANOMA; MELANOMA CELL; MITOCHONDRION; MOLECULAR MECHANICS; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR BIOPSY;

BORONIC ACIDS; CASPASE 8; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENZYME ACTIVATION; GRANZYMES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTE ACTIVATION; MELANOMA; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RECEPTORS, CELL SURFACE; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77950205394     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3175     Document Type: Article

References (31)

1. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907-920
2. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev 2001;1:142-150
3. Bleackley RC. A molecular view of cytotoxic T lymphocyte induced killing. Biochem Cell Biol 2005;83:747-751
4. Bleackley RC, Heibein JA. Enzymatic control of apoptosis. Nat Prod Rep 2001;18:431-440
5. Sutton VR, Davis JE, Cancilla M, et al. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med 2000;192:1403-1414
6. Heibein JA, Barry M, Motyka B, Bleackley RC. Granzyme B-induced loss of mitochondrial inner membrane potential (ΔPsi m) and cytochrome c release are caspase independent. J Immunol 1999;163:4683-4693
7. Goping IS, Barry M, Liston P, et al. Granzyme B-induced apoptosis requires both direct caspase activation and relief of caspase inhibition. Immunity 2003;18:355-365
8. Sutton VR, Wowk ME, Cancilla M, Trapani JA. Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 2003;18:319-329
9. Kashkar H, Seeger JM, Hombach A, et al. XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006;108:3434-3440
10. Ravi R, Fuchs EJ, Jain A, et al. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res 2006;66:1730-1739
11. Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 2008;14:1610-1617
12. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-1657
13. Abken H, Hombach A, Heuser C. Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des 2003;9:1992-2001.
14. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008;329-342
15. Nettelbeck DM, Rivera AA, Kupsch J, et al. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 2004;108:136-145
16. Hombach A, Heuser C, Sircar R, et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother 1999;22:473-480
17. Abken H, Hombach A, Heuser C, Reinhold U. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. Recent Results Cancer Res 2001;158:249-264
18. Reinhold U, Liu L, Ludtke-Handjery HC, et al. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J Invest Dermatol 1999;112:744-750
19. Hombach A, Heuser C, Abken H. Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy. Methods Mol Biol 2003;207:365-381
20. Kashkar H, Wiegmann K, Yazdanpanah B, Haubert D, Kronke M. Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem 2005;280:20804-20813
21. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-1058
22. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:525-535
23. Kashkar H, Haefs C, Shin H, et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J Exp Med 2003;198:341-347
24. Kashkar H, Deggerich A, Seeger JM, et al. NF-κB-independent downregulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 2007;109:3982-3988
25. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006;46:189-213.
26. Kim H, Rafiuddin-Shah M, Tu HC, et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006;8:1348-1358
27. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009;21:233-240
28. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005;17:393-403.
29. Kuwana T, Mackey MR, Perkins G, et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002;111:331-342
30. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007;26:1324-1337
31. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008;27:6252-6275